<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664805</url>
  </required_header>
  <id_info>
    <org_study_id>LP0133-1180</org_study_id>
    <secondary_id>2015-002079-11</secondary_id>
    <nct_id>NCT02664805</nct_id>
  </id_info>
  <brief_title>Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema</brief_title>
  <official_title>A Phase 2a, Proof of Concept Trial, Testing Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of twice daily applications of LEO 124249 ointment with LEO 124249
      ointment vehicle for up to 8 weeks in the treatment of subjects with chronic hand eczema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)</measure>
    <time_frame>56 days</time_frame>
    <description>Treatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hand Eczema Severity Index (HECSI) at visit 6</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects with treatment success according to the Patient's Global Assessment of disease severity (PaGA) at visit 6 (End of Treatment)</measure>
    <time_frame>56 days</time_frame>
    <description>Treatment success according to the PaGA is defined as: Subjects having very mild or mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or very mild</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Hand Eczema</condition>
  <arm_group>
    <arm_group_label>LEO 124249 ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily cutaneous application for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 124249 ointment vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily cutaneous application for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 124249 ointment</intervention_name>
    <description>Ointment</description>
    <arm_group_label>LEO 124249 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 124249 ointment vehicle</intervention_name>
    <description>Ointment vehicle</description>
    <arm_group_label>LEO 124249 ointment vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of chronic hand eczema with or without atopic etiology/background
             with a history of not adequately controlled disease activity with cutaneously applied
             steroid

          -  Physician's Global Assessment of disease severity graded as at least mild at Visit 1

          -  In overall good health including well controlled diseases

        Exclusion Criteria:

          -  Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine,
             azathioprine), retinoids (e.g. alitretinoin) or corticosteroids within 6 weeks prior
             to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg
             prednisone for asthma or rhinitis may be used).

          -  PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4
             weeks prior to randomization

          -  Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or
             corticosteroids on the hands within 2 weeks prior to randomization.

          -  Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2
             weeks prior to randomization

          -  Concurrent skin diseases on the hands

          -  Current diagnosis of exfoliative dermatitis

          -  Significant clinical infection (impetiginized hand eczema) on the hands which requires
             antibiotic treatment

          -  A marked abnormal ECG at baseline

          -  Known hepatic dysfunction or hepatic dysfunction tested at Screening

          -  Current participation in any other interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margitta Worm, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

